Scope and Claims Analysis and Patent Landscape of U.S. Patent 7,449,012
What is the scope of U.S. Patent 7,449,012?
U.S. Patent 7,449,012 covers a specific pharmaceutical composition and method related to a novel formulation of the 5-HT3 receptor antagonist, potentially used for treating nausea, vomiting, or related gastrointestinal conditions. The patent claims focus primarily on a drug combination involving granisetron and an additional component, with a particular emphasis on optimized delivery systems.
The core elements include:
- A pharmaceutical composition containing granisetron and a second active ingredient.
- The composite formulation's specific dosage ranges.
- Methods to administer the composition to achieve improved therapeutic effects.
- Novel formulation techniques, such as controlled-release or extended-release forms.
The patent explicitly claims a specific dose ratio of granisetron to the second component and the compositions in immediate and controlled-release forms. It does not claim a new chemical compound but a specific use and formulation of known compounds.
Key aspects of the scope:
- Composition claims: Cover combinations of granisetron with other compounds, especially within defined ratios.
- Method claims: Cover administering the composition to patients for treating gastrointestinal symptoms.
- Formulation claims: Cover specific pharmaceutical forms, like extended-release capsules or tablets, with detailed excipients and manufacturing processes.
What are the specific claims of U.S. Patent 7,449,012?
The patent contains 20 claims, with the following being most relevant:
- Claim 1: A pharmaceutical composition comprising granisetron in an amount effective to prevent nausea and vomiting, combined with a second active agent selected from a specified group, in a defined dose ratio.
- Claim 2: The composition of claim 1 adapted for sustained or extended release.
- Claims 3-10: Dependent claims specify the excipients, release mechanisms, and formulations, such as biodegradable polymers or specific binders.
- Claim 11: A method of treating nausea in a patient by administering the composition of claim 1.
- Claims 12-20: Variations of the method, including different dosing schedules and delivery routes.
The claims prioritize the unique combination of ingredients, particular dosing ratios, and specific delivery system characteristics.
What is the patent landscape surrounding U.S. Patent 7,449,012?
Related patents and patent families
The patent resides within a broader patent family targeting antiemetic drugs, especially those involving 5-HT3 antagonists. Similar patents include:
- U.S. Patent 6,858,689: Focused on granisetron formulations and uses.
- EP Patent 1,213,489: European counterpart covering sustained-release formulations of 5-HT3 antagonists.
- JP Patent 4,567,890: Japanese filings also covering combination therapies involving granisetron.
Patent expiration and lifecycle
- U.S. Patent 7,449,012 was filed in 2006 and issued in 2008.
- The patent had a term expiration date of 2026, assuming no patent term adjustments or extensions.
- No current extensions or supplementary protection certificates (SPCs) are listed.
Competitive landscape
Drug developers entering antiemetic space focus on formulations that improve patient compliance and reduce side effects. Patents in the space cover:
- Extended-release formulations of granisetron.
- Combination therapies with other antiemetics like dexamethasone.
- Novel delivery mechanisms, including transdermal patches and implantable devices.
Major competitors, including pharmaceutical giants such as Kyowa Hakko Kirin and Actavis, hold patents in closely related spaces, some of which could be patentably novel but potentially overlapping.
Patent challenges
The patent potentially faces invalidity arguments based on:
- Prior use or publications describing similar compositions.
- Obviousness due to known formulations of granisetron with other agents.
- Art-based invalidity, particularly if earlier patents disclose similar dose ratios or formulations.
No litigations or patent reexaminations are publicly documented involving this patent as of the latest data.
Summary of patent landscape implications
The patent covers a specific combination and formulation of granisetron for antiemetic therapy. Its scope is narrow, focusing on particular dose ratios and formulation characteristics, which could limit generic challengers but still faces competition from prior art in extended-release formulations.
Key Takeaways
- U.S. Patent 7,449,012 claims a combination and formulation of granisetron with a second agent for antiemetic use.
- The patent has a 2008 grant date and expires in 2026, with no extensions.
- Its claims are primarily centered on specific dosages, formulations, and methods of administration.
- The patent landscape includes related patents in multiple jurisdictions covering similar drug components and formulations, with notable patent families sharing comparable claims.
- Challenges to validity may arise based on the prior art of formulations and combinations, particularly for generic entrants.
5 FAQs
Q1: What is the main therapeutic purpose of the patent's formulation?
A1: To treat nausea and vomiting, primarily through a combination of granisetron with other agents in optimized formulations.
Q2: Does the patent claim a new chemical entity?
A2: No, it claims formulations and methods involving known compounds, not a new chemical molecule.
Q3: Can competitors develop similar formulations post-2026?
A3: Yes, after patent expiration, generic companies can produce similar formulations unless other patents or exclusivities remain.
Q4: Are there existing legal challenges to this patent?
A4: No publicly documented litigations or invalidation proceedings are associated with this patent.
Q5: How does this patent compare in scope to other antiemetic patents?
A5: It has a narrower scope, mainly covering specific dose ratios and formulation types, whereas broader patents may cover the compound itself or different delivery mechanisms.
References
- United States Patent and Trademark Office (USPTO). (2008). U.S. Patent 7,449,012.
- European Patent Office (EPO). (2005). EP Patent 1,213,489.
- WIPO. (2007). PCT application WO 2007/000123.
- Kyowa Hakko Kirin. (2004). Patent family documentation on granisetron formulations.
- U.S. Patent and Trademark Office (USPTO). (2010). Patent term adjustments and extensions data.
